Obstructive sleep apnoea syndrome - An oxidative stress disorder

Sleep Medicine Reviews

Volumn 7, Issue 1, 2003, Pages 35-51

  Lavie, Lena ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Adhesion molecules; Endothelial cells; Hypoxia reoxygenation; Monocytes; NCPAP; Oxidative stress; Reactive oxygen species; Sleep apnoea syndrome

Indexed keywords

ADENOSINE; CELL ADHESION MOLECULE; CYTOKINE; ENDOTHELIN 1; ERYTHROPOIETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN;

APNEA; ATHEROGENESIS; BIOAVAILABILITY; CELL DAMAGE; ENDOTHELIUM CELL; ENERGY METABOLISM; GENE EXPRESSION; HUMAN; HYPOXIA; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW; SLEEP APNEA SYNDROME;

EID: 0037316130     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.2002.0261     Document Type: Review

References (130)

1. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-482.
2. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent factor for uncontrolled hypertension. J Hypertens 2000; 18: 679-685.
3. Shahar E, Whitney CW, Redline S et al., for the Sleep Heart Health Study Research Group. Sleep-disordered breathing and cardiovascular disease cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
4. Young T, Peppard PE, Palta M et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157: 1746-1752.
5. Peppard P, Young, T, Palta, M, Skatrud, J. Prospective study of the association between sleep disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-1384.
6. Nieto FJ, Young TB, Lind BK et al. Association of sleep disordered breathing, sleep apnea and hypertension in a large community-based study. JAMA 2000; 283: 1829-1836.
7. De Olazabal JR, Miller MJ, Cook WR, Mithoefer JC. Disordered breathing and hypoxia during sleep in coronary artery disease. Chest 1982; 82: 548-552.
8. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336: 261-264.
9. Saito T, Yoshikawa T, Sakamoto Y, Tanaka K, Inoue T, Ogawa R. Sleep apnea in patients with acute myocardial infarction. Am J Respir Crit Care Med 1991; 19: 938-941.
10. Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. Sleep-disordered breathing in men with coronary artery disease. Chest 1996; 109: 659-663.
11. Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient ischemic attack and stroke: a prospective study of 59 patients. Neurology 1996; 47: 1167-1173.
12. Xie A, Skatrud JB, Crabtree DC, Puleo DS, Goodman BM, Morgan BJ. Neurocirculatory consequences of intermittent asphyxia in humans. J Appl Physiol 2000; 89: 1333-1339.
13. Leuenberger U, Jacob E, Sweer L, Waravdekar N, Zwillich C, Sinoway L. Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxaemia. J Appl Physiol 1995; 79: 581-588.
14. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-1904.
15. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763-1768.
16. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183-1189.
17. Carlson JT, Rangemark C, Hedner JA. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea. J Hypertens 1996; 14: 577-584.
18. Imadojemu VA, Gleeson K, Gray KS, Sinoway LI, Leuenberger UA. Obstructive apnea during sleep is associated with peripheral vasoconstriction. Am J Respir Crit Care Med 2002; 165: 61-66.
19. Dean RT, Wilcox I. Possible atherogenic effects of hypoxia during obstructive sleep apnea (Supplement: 2. Natural History of Sleep Apnea). Sleep 1993; 16: S15-S22.
20. Prabhakar RN. Physiologic and genomic consequences of intermittent hypoxia. Invited review: Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J Appl Physiol 2001; 90: 1986-1994.
21. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
22. Babior BM. Phagocytes and oxidative stress. Am J Med 2000; 109: 33-44.
23. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 2000; 108: 652-659.
24. Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000; 36: 1-30.
25. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990; 186: 1-85.
26. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271: C1421-C1437.
27. Dureanteau J, Chandel NS, Kulisz A et al. Intracellular signaling by Reactive Oxygen Species during hypoxia in Cardiomyocytes. J Biol Chem 1998; 273: 11619-11624.
28. Bouaziz N, Redon M, Quere L, Remacle J, Michiels C. Mitocondrial respiratory chain as a new target for anti-ischemic molecules. Eur J Pharmacol 2002; 441: 35-45.
29. Sanders SP, Zweier JL, Kuppusamy P et al. Hyperoxic sheep pulmonary microvascular endothelial cells generate free radicals via mitochondrial electron transport. J Clin Invest 1993; 91: 46-52.
30. Chandel NS, Maltepe E, Goldwasser E et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Procl Natl Acad Sci USA 1998; 95: 11715-11720.
31. Schulz R, Mahmoudi S, Katja Hattar et al. Enhanced release of superoxide form polymorphonuclear neutrophils in obstructive sleep apnea. Am J Respir Crit Care Med 2000; 162: 566-570.
32. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-939.
33. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266: H2568-H2572.
34. Rajogopalan S, Kurz S, Munzel T et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
35. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
36. Barcelo A, Elorza MA, Barbe F et al. Angiotensin converting enzyme in patients with sleep apnoea syndrome: plasma activity and gene polymorphisms. Eur Respir J 2001; 17: 728-732.
37. Marshall C, Mamary AJ, Verhoeven AJ, Marshall BE. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Resp Cell Mol Biol 1996; 15: 633-644.
38. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999; 34: 309-314.
39. Fletcher EC. Physiological and genomic consequences of intermittent hypoxia. Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 2001; 90: 1600-1605.
40. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the reninangiotensin system. J Appl Physiol 2002; 92: 627-633.
41. McCord MJ. Oxygen derived free radicals in post ischemic tissue injury. New Engl J Med 1985; 312: 159-163.
42. Bolli R, Jeroudi MO, Patel BS et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci USA 1989; 86: 4695-4699.
43. Bolli R, Jeroudi MO, Patel BS et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res 1989; 65: 607-622.
44. Villari B, Ambrosio G, Golino P et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125: 11-23.
45. Jolly SR, Kane WJ, Bailie MB et al. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 1984; 54: 277-285.
46. Terada LS, Dormish JJ, Shanley PF, Leff JA, Anderson BO, Repine JE. Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischaemia-reperfusion. Am J Physiol 1992; 263: L394-L401.
47. Terada LS, Guidot DM, Leff JA et al. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci USA 1992; 89: 3362-3366.
48. Findley LJ, Boykin M, Fallon T, Belardinelli L. Plasma adenosine and hypoxaemia in patients with sleep apnea. J Appl Physiol 1988; 64: 556-561.
49. Mann J, Holgate S, Renwick A, Cushley M. Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma. J Appl Physiol 1986; 61: 1667-1676.
50. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol 1986; 27: 319-349.
51. Eldridge FL, Millhorn DE, Kiley JP. Antagonism by theophylline of respirator inhibition induced by adenosine. J Appl Physiol 1985; 59: 1428-1433.
52. Mueller RA, Widerlov E, Breese GR. Attempted antagonism of adenosine analogue induced depression of respiration. Pharmacol Biochem Behav 1984;21:289-296.
53. Hasday JD, Grum CM. Nocturnal increase of urinary uric acid: creatinine ratio. A biochemical correlate of sleep-associated hypoxaemia. Am Rev Respir Dis 1987; 135: 534-538.
54. McKeon JL, Saunders NA, Murree-Allen K et al. Urinary uric acid: creatinine ratio, serum erythropoietin, and blood 2,3-diphosphoglycerate in patients with obstructive sleep apnea. Am Rev Respir Dis 1990; 142: 8-13.
55. Braghiroli A, Sacco C, Erbetta M et al. Overnight urinary uric acid: Creatinine ratio for detection of sleep hypoxaemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. Am Rev Respir Dis 1993; 148: 173-178.
56. Sahebjani H. Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 1998; 113: 1604-1608.
57. Semenza GL. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res 2000; 1: 159-162.
58. Piacentini L, Karliner JS. Altered gene expression during hypoxia and reoxygenation of the heart. Pharmacol Ther 1999; 83: 21-37.
59. Yuan G, Adhikary G, Prabhakar NR. Activation of HIF-2a by intermittent hypoxia requires CaMKII (Abstract). FASEB J 2001; 15: A154.
60. Imagawa S, Yamaguchi Y, Higuchi M et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 2001; 98: 1255-1257.
61. Schulz R, Hummel C, Heinemann S et al. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002; 165: 67-70.
62. Gozal D, Lipton AJ, Jones KL. Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea. Sleep 2002; 25: 59-65.
63. Lavie L, Kraiczi H, Hefetz et al. Plasma Vascular Endothelial Growth Factor (VEGF) in sleep apnea syndrome: effects of nCPAP treatment. Am J Respir Crit Care Med 2002; 165: 1624-1628.
64. Schultz A, Lavie L, Hochberg I et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999; 100: 547-552.
65. Gunsilius E, Petzer AL, Gastl GA. Blood levels of vascular endothelial growth factor in obstructive sleep apnea-hypopnea syndrome. (Letter to Editor) Blood 2002; 99: 393-394.
66. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 1998; 94: 395-404.
67. Carlson JT, Hedner J, Fagerber B et al. Secondary polycythaemia associated with nocturnal apnoea - a relationship not mediated by erythropoietin? J Intern Med 1992; 231: 381-387.
68. Pokala P, Llanera M, Sherwood J et al. Erythropoietin response in subjects with obstructive sleep apnea. Am J Respir Crit Care Med 1995; 151: 1862-1865.
69. Cahan C, Decker MJ, Arnold JL et al. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol 1992; 72: 2112-2117.
70. Cahan C, Decker MJ, Arnold JL et al. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol 1995; 79: 1278-1285.
71. Knaupp W, Khilnani S, Sherwood J et al. Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol 1992; 73: 837-840.
72. Ehlenz K Herzog P, von Wichert P, Kaffarnik H, Peter JH. Renal excretion of endothelin in obstructive sleep apnea syndrome. In: Gautier C, Escourrou P, Curzi-Dascalova (eds) Colloque IMSERM. John Libbey Ltd 1991; 217: 226.
73. Saarelainen S, Seppala E, Laasonen K, Hasan J. Circulating endothelin-I in obstructive sleep apnoea. Endothelium 1997; 5: 115-118.
74. Phillips BG, Narkiewicz K, Pesek CA et al. Effects of obstructive sleep apnea on endolethelin-I and blood pressure. J Hypertens 1999; 17: 61-66.
75. Trakada G, Mnangos M, Spiropoulos K. Mechanisms of endothelin-I elevation in chronic obstructive pulmonary disease patients with nocturnal oxyhaemoglobin desaturation. Respiration 2001; 68: 134-139.
76. Tahawi Z, Orolinova N, Joshua IG et al. Altered vascular reactivity in arterioles of chronic intermittent hypoxic rats. J Appl Physiol 2001; 90: 2007-2013.
77. Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001; 37:511-515.
78. Grimpen F, Kanne P, Schulz E et al. Endothelin-I plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000; 15: 320-325.
79. Saarelainen S, Hasan J. Circulating endothelin-I and obstructive sleep apnoea. Eur Respir J 2000; 16: 794-795.
80. Chin K, Ohi M, Shimzu K et al. Increase in bilirubin levels of patients with obstructive sleep apnea in the morning - a possible explanation of induced heme oxygenase-I. Sleep 2001; 24: 218-223.
81. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbances and obesity. J Clin Endocrinol Metab 1997; 82: 1313-1316.
82. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-1158.
83. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med 1996; 153: 1080-1086.
84. Chin K, Nakamura T, Shimzu K et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000; 109: 562-567.
85. Ohga E, Nagase T, Tomita T et al. Increased levels of circulating ICAM-I, VCAM-I, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999; 87: 10-14.
86. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002; 121: 1541-1547.
87. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998; 55: 1747-1758.
88. Noguchi T, Chin K, Ohi M et al. Heat shock protein 72 level decreases during sleep in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1997; 155: 1316-1322.
89. Lavie L, Ghandour H, Pillar G, Lavie P. Production of heat shock protein 70 by peripheral blood monocytes from patients with sleep apnea syndrome. J Sleep Res 1998; 7(suppl 2): 150.
90. Ghandour H, Lavie P, Lavie L. Expression of heat shock proteins in obstructive sleep apnea syndrome. Sleep 1999; 22: S331.
91. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol 2000; 15: 409-415.
92. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic Biol Med 1998; 25: 404-433.
93. Walzog B, Gaehtgens P. Adhesion molecules: the path to a new understanding of acute inflammation. News Physiol Sci 2000; 15: 107-113.
94. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114: 1066-1090.
95. Tailor A, Granger DN. Role of adhesion molecules in vascular regulation and damage. Curr Hypertens Rep 2000; 2: 78-83.
96. Rairigh RL, Storme L, Parker TA et al. Role of neuronal nitric oxide synthase in regulation of vascular and ductus arteriosus tone in the ovine fetus. Am Physiol Lung Cell Mol Physiol 2000; 278: L105-L110.
97. Rairigh RL, Le Cras TD, Ivy DD et al. Role of inducible nitric oxide synthase in regulation of pulmonary vascular tone in the late gestation ovine fetus. J Clin Invest 1998; 101: 15-21.
98. Hoffmann A, Gloe T, Pohl U. Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J Cell Physiol 2001; 188: 33-44.
99. Phelan MW, Faller DV. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 1996; 167: 469-476.
100. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26: 74-84.
101. Schulz R, Schmidt D, Blum A et al. Decreased plasma levels of nitric oxide derivative in obstructive sleep apnoea: response to nCPAP therapy. Thorax 2000; 55: 1046-1051.
102. Ip MS, Lam B, Chan LY et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162: 2166-2171.
103. Carlson J, Hedner J, Patterson A. Increased plasma concentration of ADMA a naturally occurring nitric oxide synthesis inhibitor in OSA patients. Am J Respir Crit Care Med 1997; 155: A869.
104. Ross R. Atherosclerosis - an inflammatory disease. New Eng J Med 1999; 340: 115-126.
105. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J Biol Chem 1997; 272: 20963-20966.
106. Koo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8: 348-358.
107. Navab M, Berliner JA, Watson AD et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
108. Morel DW, Hessler JR, Chisholm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-1076.
109. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96: 3264-3265.
110. Wali SO, Bahammam AS, Massaeli H et al. Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep 1998; 21: 290-296.
111. Saarelainen S, Lehtimaki T, Jaak-kola O et al. Autoantibodies against oxidised low-density lipoprotein in patients with obstructive sleep apnoea. Clin Chem Lab Med 1999; 37: 517-520.
112. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 899-900.
113. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16: 644-647.
114. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
115. Graham IM, Daly EL, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease; The European concerted action project. JAMA 1997; 277: 1775-1781.
116. Boushey CJ, Beresford SAA, Omenn GS et al, A qualitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1957.
117. Nygard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
118. Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia, J Clin Invest 1996; 98: 24-29.
119. Tawakol A, Omland T, Garhard W, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121.
120. Bellamy MF, McDowell IF, Ramsey MW et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 1848-1852.
121. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99: 1156-1160.
122. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
123. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
124. Heinecke JW, Rosen H, Sukuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
125. Eberhardt RT, Forgione MA, Cap A et al. Endothelial dysfunction in a murine model of mild hyperholocyst(e)inemia. J Clin Invest 2000; 106: 483-491.
126. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 2001; 120: 900-908.
127. Joannides R, Haefeli WE, Linder L et al. Nitric oxide is responsible for flow dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-1319.
128. Celermajer DS, Sorensen KE, Gouch VM et al. Non invasive detection of endothelial dysfunction in children and in adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
129. Kato M, Roberts-Thomson P, Phillips BG et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102: 2607-2610.
130. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxaemia during sleep. Chest 2001; 119: 1085-1091.